Dataset opportunity
Pajunk — 监管记录数据集机会
Pajunk 持有的中等规模监管记录数据集,可用于监管 RAG 和合规助手。
Score
63.3
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗器械监管事务市场规模估计为 85.9 亿美元(2026 年),预计到 2031 年将达到 141.6 亿美元,复合年增长率为 10.52%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高(专有)
Accessibility
受限
Legal
公司所有 — GDPR 敏感(需进行 PII 审查)
Buyer persona
RegTech 和合规 AI 供应商
Pajunk 的监管记录数据集提供了全面的文本模态数据集合,包括行业规范、专有知识库和历史监管提交文件。这个结构化的存储库非常适合训练监管 RAG 系统,使其能够基于公司特定的运营和法律历史,对复杂的合规和监管查询生成精确、上下文感知的答案。
该数据的商业价值体现在医疗器械监管事务市场,该市场在 2026 年的估值为 85.9 亿美元,预计将以 10.52% 的复合年增长率增长。虽然由于严格的医疗法规、GDPR、敏感的制造知识产权以及可能保守的数据共享政策,访问权限需要协商,但该数据集的稀有性及其在导航高风险医疗器械市场的直接适用性,使其成为 AI 买家独一无二的宝贵资产。⚠ 尽职调查(有价值的数据,可协商访问):临床和研发数据受严格的医疗法规和 GDPR 管辖;私营的德国中型企业可能拥有保守的数据共享政策;高精度针头的专有制造工艺高度敏感 · 公司:独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Pajunk 持有一个专有数据集,涵盖了高精度医疗器械的完整监管生命周期,从临床需求到制造。对于寻求构建先进监管 RAG 系统的RegTech 和合规 AI 供应商来说,这是一个稀有且有价值的资产。在预计到 2031 年将超过 140 亿美元的医疗器械监管市场中,该数据集通过提供导航复杂合规挑战所需的深度、上下文相关的专有数据,提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity78
主导的‘监管’,医疗保健行业,2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand92
高买家需求源于医疗器械监管事务市场的显著增长(复合年增长率 10.52%),此类专有监管数据是先进 AI 应用的基础资产。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility20
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility30
中等难度,独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型,3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有,许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 数据需求信号(0 类型)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
盈余=中等 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — Pajunk 是一个良好的目标,因为它是一家家族拥有的德国医疗器械制造商,拥有真实的运营业务,不将数据作为产品出售,并从制造和监管合规活动中产生有价值的副产品数据。问题:该公司约有 700 名员工,收入为 1.15 亿欧元,处于中小企业定义的上限。
- Deep Qualification90
✓ 通过 — Pajunk 是一家医疗器械制造商,假定的‘监管记录数据集’是其核心运营活动的连贯副产品,这些运营涉及广泛的监管合规。数据归公司所有,但由于医疗法规和知识产权,其访问权限敏感。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Regulatory records
这些文本证据表明存在详细记录与医疗专业人员协作的文档,这种协作是设备设计的基础,对于任何分析监管提交背后原理的 AI 系统都至关重要。
Industrial data
这指向了物理设备开发和制造的运营数据,提供了重要的现实世界背景,为相关的监管文本奠定了基础,并增强了其在风险评估中的价值。
Knowledge base / docs
这证实了持有者维护着一个专家级医疗内容的专业知识库,提供了一个高质量、预先验证的文本来源,非常适合训练 AI 回答复杂的临床和监管问题。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Pajunk Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global Medical Device Regulatory Affairs Market size is estimated at USD 8.59 billion in 2026, and is expected to reach USD 14.16 billion by 2031, at a CAGR of 10.52% (source: Mordor Intelligence).. Investment score 63.3/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Cargolution — 法规记录数据集机会
View opportunity →移动Zolldex — 监管记录数据集机会
View opportunity →其他Alliancedesenergies — 监管记录数据集机会
View opportunity →